Alessandro Rambaldi, MD
Investigators successfully used PET/CT scanning to determine whether patients with stage IIB to IVB Hodgkin lymphoma should switch from ABVD to BEACOPP, according to updated results from the international GITIL/FIL HD 0607 trial published in the Journal of Clinical Oncology
In previous studies, ABVD (doxorubicin, vinblastine, vincristine, and dacarbazine) has been associated with a 3- to 5-year progression-free survival (PFS) ranging from 61% to 76%. The more intensive BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen has shown superior disease control, with a 5-year freedom from treatment failure of up to 90%, but at the cost of increased toxicity. BEACOPP has been associated with increased hematologic toxicity, a high incidence of sterility, and severe late complications/long-term toxicities including a 5-year cumulative risk for myelodysplastic syndrome or acute leukemia of 2.2% compared with 0.4% for ABVD.
... to read the full story